Although these chemotherapeutics are not a part of the standard protocol in GBM, one VEGF inhibitor, namely Bevacizumab, a monoclonal antibody, has been approved for the treatment of recurrent GBM after several clinical trials proving its benefit [95,96]. The gene discussed is VEGFA; the disease is glioblastoma.